Literature DB >> 24674866

BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients.

Olga Meltem Akay1, Beyhan Durak Aras2, Serap Isiksoy3, Cigdem Toprak2, Fezan Sahin Mutlu4, Sevilhan Artan2, Ulku Oner3, Zafer Gulbas5.   

Abstract

The purpose of this study was to determine the frequency of BCL2, BCL6, IGH, TP53, and MYC protein expression and rearrangements of the respective genes in diffuse large B-cell lymphoma (DLBCL) patients and to assess their prognostic values. Samples from 44 patients with DLBCL were evaluated using fluorescence in situ hybridization and immunohistochemical analyses. BCL6 was the most rearranged gene (63.6%), followed by MYC (31.8%), TP53 (22.7%), and BCL2 (18.2%). Multiple rearrangements were detected in 40.9% of the cases. BCL6 was the most expressed protein (78.6%), followed by TP53 (69.04%), BCL2 (59.5%) and MYC (14.3%). Expression of multiple proteins was detected in 67.4% of the cases. BCL2 (P = .003) expression had a significant negative influence on overall survival,whereas BCL6 (P = .014) expression had a significant positive influence. Our results with a different pattern of gene rearrangements and associated protein overexpression indicate the molecular genetic complexity of DLBCLs, which reflects the morphologic, biologic, and clinical heterogeneity of these lymphomas.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCL2; BCL6; MYC; TP53; diffuse large B-cell lymphoma

Mesh:

Substances:

Year:  2014        PMID: 24674866     DOI: 10.1016/j.cancergen.2014.02.001

Source DB:  PubMed          Journal:  Cancer Genet


  8 in total

1.  Mutual interaction between BCL6 and microRNAs in T cell differentiation.

Authors:  Zhiyuan Wei; Weiwu Gao; Yuzhang Wu; Bing Ni; Yi Tian
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

2.  AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.

Authors:  J Jiao; Y Jin; M Zheng; H Zhang; M Yuan; Z Lv; W Odhiambo; X Yu; P Zhang; C Li; Y Ma; Y Ji
Journal:  Clin Exp Immunol       Date:  2018-11-13       Impact factor: 4.330

3.  Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.

Authors:  Seul Lee; Dong Hyun Kim; Sung Yong Oh; So Yeon Kim; Myeong Seok Koh; Ji Hyun Lee; Suee Lee; Sung-Hyun Kim; Jong-Young Kwak; Min Gyoung Pak; Mi Ha Ju; Hyo-Jin Kim; Jin Sook Jeong
Journal:  Korean J Intern Med       Date:  2016-03-11       Impact factor: 2.884

4.  BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies.

Authors:  Shu Li; Zhan Wang; Liming Lin; Zhaoxing Wu; Qingfeng Yu; Feiqiong Gao; Jiawei Zhang; Yang Xu
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

5.  The survival decrease in gastric cancer is associated with the methylation of B-cell CLL/lymphoma 6 member B promoter.

Authors:  Jingyu Deng; Han Liang; Qiuping Dong; Yachao Hou; Xingming Xie; Jun Yu; Daiming Fan; Xishan Hao
Journal:  Open Biol       Date:  2014-07       Impact factor: 6.411

6.  MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.

Authors:  Ting-Xun Lu; Lei Fan; Li Wang; Jia-Zhu Wu; Kou-Rong Miao; Jin-Hua Liang; Qi-Xing Gong; Zhen Wang; Ken H Young; Wei Xu; Zhi-Hong Zhang; Jian-Yong Li
Journal:  Oncotarget       Date:  2015-07-30

7.  Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.

Authors:  Ana-Iris Schiefer; Christoph Kornauth; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Eva Katharina Masel; Berthold Streubel; Katrina Vanura; Karin Walter; Brigitta Migschitz; Dagmar Stoiber; Veronika Sexl; Markus Raderer; Andreas Chott; Maria Gomes da Silva; Jose Cabecadas; Leonhard Müllauer; Ulrich Jäger; Edit Porpaczy
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

8.  The plasma peptides of breast versus ovarian cancer.

Authors:  Jaimie Dufresne; Pete Bowden; Thanusi Thavarajah; Angelique Florentinus-Mefailoski; Zhuo Zhen Chen; Monika Tucholska; Tenzin Norzin; Margaret Truc Ho; Morla Phan; Nargiz Mohamed; Amir Ravandi; Eric Stanton; Arthur S Slutsky; Claudia C Dos Santos; Alexander Romaschin; John C Marshall; Christina Addison; Shawn Malone; Daren Heyland; Philip Scheltens; Joep Killestein; Charlotte Teunissen; Eleftherios P Diamandis; K W M Siu; John G Marshall
Journal:  Clin Proteomics       Date:  2019-12-23       Impact factor: 3.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.